You are here: Industry Insights > Sagent

News List

Sagent Recalls Phenylephrine Hydrochloride Injection americanpharmaceuticalreview
March 19, 2021
Sagent Pharmaceuticals announced the voluntary nationwide recall of three lots of Phenylephrine Hydrochloride Injection, USP (10 mg/mL). This product was manufactured by Indoco Remedies Ltd. and distributed by Sagent Pharmaceuticals, Inc. Sagent has ...
Sagent Begins NIAID-Sponsored Study Investigating Outpatient COVID-19 Treatments americanpharmaceuticalreview
February 18, 2021
Sagent Pharmaceuticals announced Camostat mesilate, is one of four therapies being added to the existing ACTIV-2 Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID), which was launched by the National Institutes of Health ...
Sagent Launches Phase 2 Trial to Evaluate Camostat Mesilate for COVID-19 americanpharmaceuticalreview
November 24, 2020
Sagent Pharmaceuticals, a Nichi-Iko Group Company, has launched its Phase 2 CAMELOT trial to evaluate the safety and efficacy of Camostat Mesilate (Camostat) for the treatment of COVID-19 in high-risk outpatients and has begun enrolling patients.
Pii to Manufacture FDA-Approved Hormone Therapy Injection Drug Product contractpharma
September 24, 2019
Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) headquartered in Hunt Valley, MD, will manufacture commercial supply of Fulvestrant Injection 250mg/5ml drug product ...